F. Hoffmann-La Roche Ltd: Roche's BTK inhibitor fenebrutinib

Fenebrutinib is an investigational, potent and highly selective oral Bruton's tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase

Related Keywords

Japan , Switzerland , United States , America , Bruno Eschli , Sabine Borngr , Nathalie Altermatt , Gerard Tobin , Levi Garraway , Loren Kalm , Gewinn Nur , Kirti Pandey , Birgit Masjost , Roche Group Media Relations , Roche Group , Head Of Global Product Development , Genentech , Chief Medical Officer , Global Product , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Hoffmann , Oche , Inhibitor , Fenebrutinib , Ignificantly , Educed , Rain , Sesions , People , Relapsing , Eforms , Multiple , Clerosis ,